PCIERD Anniversary June 2014

How to Start, Grow and Sell a Biotech/Medical Device Company in United States: The Xylos Story

Al Serafica, PhD Chem Eng'g June 27, 2014




Presentation Outline

- Pre Start-up (1993-1996)
- Starting the company (1996-1998)
- First Product Launch (2000-2003)
- Growing the company (2003- 2012)
- Selling the company (2007-2012)




Bacterial Nanocellulose



Cellulose Fiber (1-10 nanometers width)



Active Culture



Top View

Acetobacter xylinum



Full Pellicle

Biocellulose



How I got involved with BC?

Nata de Coco boom of 1993 in the Philippines

- Focused on biopolymer production optimization
- Completing PhD in Chemical Eng'g in RPI
- Filed 1st Patent in 1995 in U.S. granted in 1999



How Xylos got started?

- Met an RPI Alumni business partner at university enterprise forum in 1995
- Founded Xylos in August 1996
- Received NIH SBIR grant for bacterial cellulose wound dressing in 1997
- Received first FDA clearance in 1998



Initial Technical Challenges

- Shift from research to product development
- Expand knowledge of potential applications
- Identify the first product and its advantages
- Complete regulatory requirements
- Develop clinical experience to help marketing



Enterprise Challenges

- Recruiting early stakeholders-RPI
- Raising the first venture financing
- Completing management team
- Identifying path to market
 - marketing partner and clinical support



Key Milestones of 1st VC Funding

- 1. Finish Wound Dressing development
- 2. Biocompatibility testing completed
- 3. FDA application filed/cleared
- 4. Successful animal testing and Clinical
- 5. IP position testing expanded



First Product Launch 2003

5 year to launch and 3 partnerships

- Scaled up Manufacturing and CE mark
- Expanded multi-center clinical testing
- Second FDA product: antimicrobial dressing



Scientist's Changing Roles

- Technology Pitch
- Competitive advantage
- Regulatory Clearance
- Pre-clinical and Clinical testing focus on best application
- Providing marketing support



First Implantable Product 2003

- Focus on permanent implant
- Completed prototype and safety testing
- Animal effectiveness testing
- Search for product Champion
- 1st CRADA with a corporate partner



Expand Implantable Applications

- More human body locations (2006-2012)
- High-strength tissue reinforcement
- Soft tissue adhesion prevention
- Vessel Guard applications
- Complete regulatory requirements bioresorbable
- Develop clinical experience to help marketing



At the end of 16 year adventure

- Five distinct product groups
- 7 FDA products cleared/ 2 CE approved
- FDA Registered ISO Facility
- Received 10 U.S granted patents and 20 IP
- Sold Topical and Implantable to partners



On Selling the company

- Expanding Technology/Clinical Use
- Proven Regulatory Pathway
- Worldwide Intellectual Property
- High Market potential
- Easy Manufacturing Scale up
- Reduce the RISKS!



Method of Analysis: TRIM³

- Technology focus/advantage
- Regulatory Pathway
- Intellectual Property
- Market potential
- Manufacturing Scale up
- Money is it worth doing it?

ROI (Return on Investment)!!!

Some Lessons Learned

- Dare to dream
- One cannot have too many friends
- You cannot do it all
- Control is an elusion
- Failure is not option



Acknowledgements

- Xylos employees
- Venture Capital Groups
- Product Champions- Doctors/Nurses
- Marketing partners- Corporate
- Early supporters, NIH-SBIR and RPI



Thank You!!

alserafica@hotmail.com

